What are the recommended treatments for a patient experiencing an eosinophilic esophagitis (EoE) flare?

Treatment of Eosinophilic Esophagitis Flare

For an EoE flare, initiate swallowed topical corticosteroids as first-line therapy, with proton pump inhibitors (PPIs) as an alternative first-line option, particularly if cost or access is a concern. 1

Primary Treatment Options

Topical Corticosteroids (Preferred First-Line)

• Swallowed topical corticosteroids fail to induce histologic remission in only one-third of patients, compared to >85% failure with placebo 1
• Formulations include:
  • Budesonide orodispersible tablets (approved in Europe, Canada, Australia for adults; approved in USA for adolescents ≥11 years and adults) 2
  • Fluticasone (2 puffs 4 times daily: 110μg/puff for age <10 years, 220μg/puff for age 11-18 years) 1
  • Budesonide suspension (viscous formulations designed to coat esophageal mucosa)
• Efficacy: 65-72% symptomatic response, with moderate certainty of evidence 1
• Safety: Short-term studies (≤3 months) show no increased adverse events versus placebo; main side effect is oral candidiasis (15%) 1

Proton Pump Inhibitors (Alternative First-Line)

• Double-dose PPI induces remission in approximately 50% of EoE patients 3
• Most accessible and lowest cost option with excellent safety profile 3
• Anti-inflammatory effects are independent of acid suppression 3
• Very low certainty of evidence with inconsistent results compared to topical steroids 2
• Standard doses maintain long-term remission in most responders 3

Topical vs Systemic Steroids

Use topical corticosteroids rather than oral prednisone 1. While both achieve similar symptomatic improvement (72% prednisone vs 65% fluticasone), systemic steroids cause significantly more adverse effects (40% systemic complications including weight gain and cushingoid appearance vs 15% oral candidiasis with topical therapy) 1

Second-Line and Adjunctive Therapies

Dupilumab (Biologic)

• Approved for patients ≥12 years (≥40 kg) who are unresponsive, intolerant, or not candidates for conventional therapies 2
• Targets IL-4 and IL-13 pathways
• Achieves ~60% histologic remission 4
• Unlikely to replace PPIs or topical steroids as first-line except in specific circumstances 5

Dietary Elimination

• Six-food elimination diet (SFED) is conditionally recommended over no treatment 1
• Elemental diet achieves histologic remission in 93.6% of patients but has significant adherence challenges 1
• Step-up strategies (2-food or 4-food elimination) reduce endoscopic procedures and unnecessary restrictions 3
• Allergy testing-based elimination has very low quality evidence due to limited accuracy 1

Endoscopic Dilation

• Recommended for dysphagia from strictures 1
• 87% of patients experience symptom improvement 1
• Does NOT address underlying inflammation—must be combined with anti-inflammatory therapy 1, 6
• Perforation rate 0.4%, hospitalization 1.2%, with improved safety using conservative approach 1

Maintenance Therapy

Continue topical corticosteroids after achieving remission rather than discontinuing treatment 1. Discontinuation leads to return of symptoms and disease activity in most patients 1. The limited data on maintenance therapy shows:

• Low-dose budesonide (0.25 mg twice daily) maintained <5 eos/hpf in only 36% at 1 year 1
• PPIs show sustained histologic response in majority of adults despite dose reduction 1
• Relapse rates are 45% at 24 weeks after stopping therapy 1

Treatment Algorithm

1. Initial flare: Start swallowed topical corticosteroids (budesonide or fluticasone) OR double-dose PPI
2. Duration: Treat for 8-12 weeks, then reassess with endoscopy and biopsy
3. If responsive: Continue maintenance therapy at same or reduced dose
4. If non-responsive to topical steroids: Switch to PPI (if not tried) or consider dupilumab
5. If stricture present: Add endoscopic dilation while continuing anti-inflammatory therapy
6. Dietary therapy: Consider empiric 2-4-6 step-up elimination diet if patient prefers non-pharmacologic approach

Critical Pitfalls to Avoid

• Do not use systemic steroids except in refractory cases—similar efficacy but significantly worse side effects 1
• Do not rely on allergy testing to guide food elimination—very low accuracy 1
• Do not perform dilation alone without addressing inflammation—it does not treat the underlying disease 1, 6
• Do not discontinue therapy after initial remission without close follow-up—disease recurs in most patients 1
• Inflammatory phenotype responds better than stricturing phenotype—treat early to prevent fibrosis 3

Therapies NOT Recommended

The following have failed efficacy or unfavorable safety profiles: montelukast, azathioprine, infliximab, vedolizumab, mepolizumab, reslizumab, benralizumab, omalizumab 2, 7